Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Microbiome
Sort By
Newest First
1 / 3
1 / 3
LBPs
Exploring the Microbiome with Servatus
Servatus
PAO-11-24-RTM-14
Nov 18, 2024
Advanced Therapies
A New Vision for Progressing Advanced Therapies
Nathaniel Youndt
ReciBioPharm
PAO-10-24-CL-13
Oct 25, 2024
Microbiome
Modifying the Gut Microbiome to Improve CAR-T, HSCT, and Other Therapeutic Responses
Stacy Burns-Guydish, Ph.D.
List Labs
PAO-10-23-CL-07-33
Nov 01, 2023
Microbiome Therapeutic Innovation
Unleashing the Power of the Microbiome: Advancements, Challenges, and the Therapeutic Future
Stacy Burns-Guydish, Ph.D.; Gary Henderson
List Labs
PAO-03-23-CL-08
Apr 04, 2023
Microbiome-Based CDMO
Expanding a Leadership Position in Microbiome-Based Contract Development and Manufacturing
Stacy Burns-Guydish, Ph.D.; Jonathan Yongwan Jo; Gary Henderson; Michael Kimble
List Labs
PAO-11-022-CL-13
Dec 13, 2022
Diabetes Research
Composition of Gut Microbiome Predicts the Onset of Type 2 Diabetes
University of Turku
PR-M02-22-13
Feb 16, 2022
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Aaron B. Cowley, Ph.D.; Nicole O'Brien, Ph.D.
ReciBioPharm
PAO-09-21-CL-11
Sep 28, 2021
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
Aaron B. Cowley, Ph.D.; Judith Bodette; Brian Duffy
ReciBioPharm
PAO-06-21-CL-10
Jun 25, 2021
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
Aaron B. Cowley, Ph.D.; Melanie Cerullo; Jeff Heiser
ReciBioPharm
PAO-06-21-CL-05
Jun 14, 2021
Microbiome
Understanding the Link Between Gut Health and Disease
Dr. Sabine Hazan
ProgenaBiome
PTV-05-21-CL-004
May 27, 2021
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
Pharma's Almanac
PAO-03-21-NI-01
Mar 16, 2021
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
Arranta Bio
PR-M03-21-002-1066
Mar 08, 2021
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Susan Surabian; Melanie Cerullo
Arranta Bio
PAP-Q4-20-CL-002
Dec 09, 2020
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
Arranta Bio
PAP-Q4-20-RT2-007
Dec 09, 2020
Gene Editing
Enhancing Human Gut Tissue Models through Gene Editing
Scott Magness, Ph.D.
Altis Biosystems
PAO-11-20-CL-03
Nov 30, 2020
Microbiome
Evaluating Microbiome Therapies with Intestinal Cell Models
Scott Magness, Ph.D.
Altis Biosystems
PAO-10-20-CL-02
Oct 22, 2020
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
Aaron B. Cowley, Ph.D.
ReciBioPharm
PAP-Q3-20-CL-004
Sep 29, 2020
Design Logic
Experience to Solve Your Microbiome Challenges
Nice Insight
PAP-Q3-20-NI-010
Sep 29, 2020
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
Arranta Bio
PAP-Q3-20-RT2-009
Sep 29, 2020
Microbiome
Selecting a Microbiome CDMO Partner for the Long Term
Dave Stevens; Jason Rahal
Arranta Bio
PAP-Q2-20-CL-008
Jul 01, 2020
